MANKIND PHARMA LIMITED (MANKIND) financials

MANKIND PHARMA LIMITED (MANKIND) NSE/BSE financials on Fincrux: quarterly results, profit and loss, cash flow, balance sheet, ratios, and shareholding.

Incorporated in 1995, Mankind Pharma Limited develops, manufactures, and markets pharmaceutical formulations in various acute and chronic therapeutic areas and several consumer healthcare products.[1]

Market Cap: ₹96,446Cr.
Current Price: ₹2,335
Stock P/E: 42.6
ROE: 13.8%
ROCE: 13.7%
Book Value: ₹397
Dividend Yield: 0.04%
52W High / Low: ₹2,642/1,910

In Jun 2026, MANKIND PHARMA LIMITED (MANKIND) reported sales ₹2,964 Cr and net profit ₹558 Cr.

Annual TTM: sales ₹10,787 Cr, net profit ₹2,180 Cr.

Shareholding: Promoters 72.63% (Jun 2026), FIIs 9.45% (Jun 2026), DIIs 15.39% (Jun 2026), Public 2.53% (Jun 2026), No. of Shareholders 1,66,715% (Jun 2026).

MANKIND quarterly results (₹ Cr.)
Category	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026	Jun 2026
Sales	2,544	2,414	2,119	2,570	2,609	2,633	2,582	2,964
Expenses	1,781	1,668	1,778	1,885	1,916	1,854	1,663	2,035
Operating Profit	763	746	342	685	693	778	919	929
OPM %	30%	31%	16%	27%	27%	30%	36%	31%
Other Income	139	70	220	65	78	-27	104	34
Interest	3	200	162	149	147	138	125	95
Depreciation	90	91	115	105	99	108	109	111
Profit before tax	810	525	284	496	525	505	788	757
Tax %	20%	22%	16%	16%	13%	11%	9%	26%
Net Profit	645	412	238	415	459	449	714	558
EPS in Rs	16.11	9.99	5.77	10.06	11.12	10.87	17.29	13.52
Raw PDF	—	—	—	—	—	—	—	—

MANKIND profit and loss (₹ Cr.)
Category	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026	TTM
Sales	4,794	5,530	7,486	8,127	8,629	9,507	10,421	10,787
Expenses	3,550	4,151	5,644	6,429	6,358	7,082	7,333	7,468
Operating Profit	1,244	1,379	1,842	1,698	2,272	2,425	3,088	3,319
OPM %	26%	25%	25%	21%	26%	26%	30%	31%
Other Income	94	148	200	163	369	555	218	189
Interest	11	8	48	28	17	378	562	506
Depreciation	62	78	123	270	335	395	429	427
Profit before tax	1,265	1,440	1,871	1,563	2,289	2,208	2,315	2,574
Tax %	24%	25%	26%	20%	18%	19%	12%	—
Net Profit	958	1,084	1,389	1,248	1,876	1,786	2,038	2,180
EPS in Rs	23.92	27.07	34.68	31.16	46.84	43.29	49.36	52.80
Dividend Payout %	32%	0%	0%	0%	0%	0%	2%	—

MANKIND balance sheet (₹ Cr.)
Category	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Equity Capital	40	40	40	40	40	40	41	41
Reserves	3,025	3,611	4,694	6,500	7,744	9,663	14,281	16,356
Borrowings	190	3	101	688	5	24	7,383	5,571
Other Liabilities	596	877	1,045	1,710	1,583	1,790	2,752	2,658
Total Liabilities	3,851	4,531	5,880	8,939	9,371	11,516	24,458	24,625
Fixed Assets	778	945	987	2,927	3,142	3,552	4,076	3,926
CWIP	211	148	166	387	495	209	207	420
Investments	1,698	1,784	2,397	2,526	3,102	4,215	16,683	16,523
Other Assets	1,164	1,655	2,330	3,100	2,632	3,540	3,491	3,756
Total Assets	3,851	4,531	5,880	8,939	9,371	11,516	24,458	24,625

MANKIND cash flows (₹ Cr.)
Category	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Cash from Operating Activity	537	960	1,022	821	1,799	1,736	2,350	2,752
Cash from Investing Activity	-306	-396	-1,127	-1,360	-1,041	-1,665	-12,178	-388
Cash from Financing Activity	-240	-559	89	579	-710	-5	9,816	-2,477
Net Cash Flow	-9	5	-16	40	48	66	-11	-113
Free Cash Flow	371	795	830	-1,360	1,219	1,456	1,996	2,317
CFO/OP	111%	99%	103%	70%	123%	95%	116%	104%

MANKIND shareholding pattern (%)
Category	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026	Jun 2026
Promoters	74.87%	72.71%	72.70%	72.67%	72.67%	72.66%	72.66%	72.63%
FIIs	12.37%	13.34%	12.92%	13.07%	12.83%	11.34%	10.24%	9.45%
DIIs	9.91%	11.05%	11.47%	11.50%	11.91%	13.26%	14.46%	15.39%
Public	2.86%	2.89%	2.89%	2.75%	2.57%	2.75%	2.63%	2.53%
No. of Shareholders	1,63,854	1,71,281	1,80,597	1,79,549	1,70,347	1,77,539	1,77,606	1,66,715

MANKIND key ratios
Category	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Debtor Days	13	32	24	23	22	33	35	41
Inventory Days	126	124	169	183	132	160	154	151
Days Payable	101	113	122	133	103	75	80	95
Cash Conversion Cycle	38	43	72	73	52	118	109	97
Working Capital Days	44	41	42	26	40	55	-81	-87
ROCE %	22%	36%	33%	30%	21%	24%	15%	14%

MANKINDUpdated 15 Oct 2026, 5:46

Mankind Pharma Limited

MANKINDUpdated 15 Oct 2026, 5:46

Market Cap

₹96,446Cr.

Current Price

₹2,335

High / Low

₹2,642/1,910

Stock P/E

42.6

ROE13.8%

ROCE13.7%

Book Value₹397

Face Value₹1.00

Dividend Yield0.04%

About

Quarterly results

Last reported quarters₹ Cr.

Quarter	Sales	Interest	Expenses	Other Income	Depreciation	Profit Before Tax	Tax	Net Profit	EPS (₹)
Jun 2023	2092	2	1594	87	69	514	20	409	10.22
Sep 2023	2260	4	1662	84	77	601	21	473	11.8
Dec 2023	2209	4	1636	92	90	571	15	487	12.16
Mar 2024	2007	4	1482	109	87	543	14	468	11.68
Jun 2024	2413	7	1837	125	91	603	16	506	12.62
Sep 2024	2544	3	1781	139	90	810	20	645	16.11
Dec 2024	2414	200	1668	70	91	525	22	412	9.99
Mar 2025	2119	162	1778	220	115	284	16	238	5.77
Jun 2025	2570	149	1885	65	105	496	16	415	10.06
Sep 2025	2609	147	1916	78	99	525	13	459	11.12
Dec 2025	2633	138	1854	-27	108	505	11	449	10.87
Mar 2026	2582	125	1663	104	109	788	9	714	17.29
Jun 2026	2964	95	2035	34	111	757	26	558	13.52

Profit & loss

Annual statement₹ Cr.

Year	Sales	Interest	Expenses	Other Income	Depreciation	Profit Before Tax	Tax	Net Profit	EPS (₹)
Mar 2018	3918	18	3141	209	28	941	26	694	17.33
Mar 2019	3829	40	3124	64	38	691	26	514	12.83
Mar 2020	4794	11	3550	94	62	1265	24	958	23.92
Mar 2021	5530	8	4151	148	78	1440	25	1084	27.07
Mar 2022	7486	48	5644	200	123	1871	26	1389	34.68
Mar 2023	8127	28	6429	163	270	1563	20	1248	31.16
Mar 2024	8629	17	6358	369	335	2289	18	1876	46.84
Mar 2025	9507	378	7082	555	395	2208	19	1786	43.29
Mar 2026	10421	562	7333	218	429	2315	12	2038	49.36
TTM	10787	506	7468	189	427	2574	—	2180	52.8

Shareholding pattern

As of Jun 2026%

Holder	Share
Promoters	72.63%
FIIs	9.45%
DIIs	15.39%
Public	2.53%

Shareholding trend

Ownership over time%

Quarter	Promoters	FIIs	DIIs	Public
Sep 2023	76.5%	4.18%	4.56%	14.76%
Dec 2023	76.5%	6.74%	9.78%	6.97%
Mar 2024	74.88%	9.87%	11.14%	4.1%
Jun 2024	74.87%	11.58%	9.94%	3.61%
Sep 2024	74.87%	12.37%	9.91%	2.86%
Dec 2024	72.71%	13.34%	11.05%	2.89%
Mar 2025	72.7%	12.92%	11.47%	2.89%
Jun 2025	72.67%	13.07%	11.5%	2.75%
Sep 2025	72.67%	12.83%	11.91%	2.57%
Dec 2025	72.66%	11.34%	13.26%	2.75%
Mar 2026	72.66%	10.24%	14.46%	2.63%
Jun 2026	72.63%	9.45%	15.39%	2.53%

Balance sheet

Assets & liabilities₹ Cr.

Period	Equity Capital	Reserves	Borrowings	Other Liabilities	Total Liabilities	Fixed Assets	CWIP	Investments	Other Assets	Total Assets
Mar 2018	40	2957	360	652	4009	534	322	1402	1751	4009
Mar 2019	40	3025	190	596	3851	778	211	1698	1164	3851
Mar 2020	40	3611	3	877	4531	945	148	1784	1655	4531
Mar 2021	40	4694	101	1045	5880	987	166	2397	2330	5880
Mar 2022	40	6500	688	1710	8939	2927	387	2526	3100	8939
Mar 2023	40	7744	5	1583	9371	3142	495	3102	2632	9371
Mar 2024	40	9663	24	1790	11516	3552	209	4215	3540	11516
Mar 2025	41	14281	7383	2752	24458	4076	207	16683	3491	24458
Mar 2026	41	16356	5571	2658	24625	3926	420	16523	3756	24625

Cash flows

Operating, investing & financing₹ Cr.

Period	Operating	Investing	Financing	Net cash flow
Mar 2018	540	-516	8	31
Mar 2019	537	-306	-240	-9
Mar 2020	960	-396	-559	5
Mar 2021	1022	-1127	89	-16
Mar 2022	821	-1360	579	40
Mar 2023	1799	-1041	-710	48
Mar 2024	1736	-1665	-5	66
Mar 2025	2350	-12178	9816	-11
Mar 2026	2752	-388	-2477	-113

Key ratios

Historical financial ratios

Category	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Debtor Days	23	13	32	24	23	22	33	35	41
Inventory Days	120	126	124	169	183	132	160	154	151
Days Payable	115	101	113	122	133	103	75	80	95
Cash Conversion Cycle	27	38	43	72	73	52	118	109	97
Working Capital Days	95	44	41	42	26	40	55	-81	-87
ROCE %	—	22%	36%	33%	30%	21%	24%	15%	14%

Frequently asked questions

Quick answers about this company's financials on Fincrux

What is the market cap of MANKIND PHARMA LIMITED (MANKIND)?

The reported market capitalisation for MANKIND PHARMA LIMITED (MANKIND) is ₹96,446Cr. on Fincrux. Figures may update with market data and filings.

What is the current share price of MANKIND?

The current price shown for MANKIND PHARMA LIMITED (MANKIND) on Fincrux is ₹2,335 with a 52-week high/low of ₹2,642/1,910.

What is the P/E ratio of MANKIND PHARMA LIMITED (MANKIND)?

The stock P/E for MANKIND PHARMA LIMITED (MANKIND) is 42.6 on Fincrux, with ROE at 13.8% and ROCE at 13.7%.

What were MANKIND latest quarterly results?

For Jun 2026, MANKIND PHARMA LIMITED (MANKIND) reported sales ₹2,964 Cr and net profit ₹558 Cr (figures in ₹ crore unless noted).

What are MANKIND annual sales and net profit?

For TTM, MANKIND PHARMA LIMITED (MANKIND) shows sales of ₹10,787 Cr and net profit of ₹2,180 Cr on the Fincrux profit & loss statement.

Who owns MANKIND PHARMA LIMITED (MANKIND)?

Latest shareholding for MANKIND PHARMA LIMITED (MANKIND) on Fincrux: Promoters 72.63% (Jun 2026), FIIs 9.45% (Jun 2026), DIIs 15.39% (Jun 2026), Public 2.53% (Jun 2026), No. of Shareholders 1,66,715% (Jun 2026).

Where can I find MANKIND PHARMA LIMITED (MANKIND) financials?

MANKIND PHARMA LIMITED (MANKIND) financials on Fincrux include quarterly results, profit and loss, cash flow, balance sheet, key ratios, and shareholding patterns for NSE/BSE research.

Does Fincrux show MANKIND balance sheet and cash flow?

Yes. The MANKIND PHARMA LIMITED (MANKIND) page on Fincrux includes balance sheet, cash flow statements, historical ratios, and ownership trends alongside quarterly and annual results.

Figures in ₹ crore unless noted. Data sourced for research and may lag filings.

Last updated 15 October 2026 at 5:46